Volume 10, Number 10—October 2004
Dispatch
Mycobacterium triplex Pulmonary Disease in Immunocompetent Host
Table 1
Clinical and microbiological features of pulmonary infection with Mycobacterium triplexa
Characteristic | Patient described in reference 15 | Patient described in reference 16 | Our patient |
---|---|---|---|
Age/Sex | 67/F | 54/F | 54/F |
Symptoms | Hemoptysis | Cough, hemoptysis, fever, fatigue | Cough, fatigue |
Findings | Bronchiectases, lung nodules | Lung infiltrates and nodule (0.3 cm) | Bronchiectases, lung nodules, cavitations |
Collected samples (no.) | Bronchial aspirate (1), sputum (3) | BAL (2), sputum (4) | Bronchial aspirate (7), BAL (2) |
Smear-positive | None | None | 6 |
Culture-positive | 3 | 3 | 9 |
Mean no. CFU/mL (range) | NR | NR | 693 (144–2,772) |
In vitro testing | |||
S | RMP, SM, CLA | NR | CLA |
I | CIP | NR | AN, CIP, EMB, ETH, RBT, SM |
R | EMB, INH, PZA | NR | INH, RMP |
Therapeutic schedule (mo.) | RMP, CIP, EMB, CLA (18) | RMP, INH, CLA (NR) | INH, RMP, EMB (6); EMB, CLA (9); LVX, CLA, EMB (9) |
Outcome | Healed | NR | Slight improvement |
aBAL, bronchoalveolar lavage; NR, not reported; S, susceptible; I, moderately susceptible; R, resistant; RMP, rifampin; SM, streptomycin; CLA, clarithromycin; CIP, ciprofloxacin; AN, amikacin; EMB, ethambutol; ETH, ethionamide; RBT, rifabutin; INH, isoniazid; PZA, pyrazinamide; LVX, levofloxacin.
References
- Primm TP, Lucero CA, Falkinham JO III. Health impacts of environmental mycobacteria. Clin Microbiol Rev. 2004;17:98–106. DOIPubMedGoogle Scholar
- Falkinham JO III. Mycobacterial aerosols and respiratory disease. Emerg Infect Dis. 2003;9:763–7.PubMedGoogle Scholar
- American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:S1–25.PubMedGoogle Scholar
- Floyd MM, Guthertz LS, Silcox VA, Duffey PS, Jang I, Desmond EP, Characterization of an SAV organism and proposal of Mycobacterium triplex sp. nov. J Clin Microbiol. 1996;34:2963–7.PubMedGoogle Scholar
- Selvarangan R, Whei-Kuo W, Trang TN, Carlson LDC, Wallis CK, Stiglich SK, Characterization of a novel group of mycobacteria and proposal of Mycobacterium sherrisii sp. nov. J Clin Microbiol. 2004;42:52–9. DOIPubMedGoogle Scholar
- Springer B, Whei-Kuo W, Bodmer T, Haase G, Pfyffer GE, Kroppenstedt RM, Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol. 1996;34:1100–7.PubMedGoogle Scholar
- Cingolani A, Sanguinetti M, Antinori A, Larocca LM, Ardito F, Posteraro B, Disseminated mycobacteriosis caused by drug-resistant Mycobacterium tripex in a human immunodeficiency virus–infected patient during highly active antiretroviral therapy. Clin Infect Dis. 2000;31:177–9. DOIPubMedGoogle Scholar
- Hoff E, Sholtis M, Procop G, Sabella C, Goldfarb J, Willie R, Mycobacterium tripex infection in a liver transplant patient. J Clin Microbiol. 2001;39:2033–4. DOIPubMedGoogle Scholar
- Zeller V, Nardi AL, Truffot-Pernot C, Sougakoff V, Stankoff B, Katlama C, Disseminated infection with a mycobacterium related to Mycobacterium tripex with central nervous system involvement associated with AIDS. J Clin Microbiol. 2003;41:2785–7. DOIPubMedGoogle Scholar
- Metchock B, Nolte FS, Wallace RJ Jr. Mycobacterium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 7th ed. Washington: ASM Press; 1999. p. 399–437.
- Tortoli E, Mariottini A, Mazzarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J Clin Microbiol. 2003;41:4418–20. DOIPubMedGoogle Scholar
- Tortoli E, Bartoloni A. Burrini, Mantella A, Simonetti MT. Utility of high performance liquid chromatography for identification of mycobacterial species rarely encountered in clinical laboratories. Eur J Clin Microbiol Infect Dis. 1995;14:240–3. DOIPubMedGoogle Scholar
- Harmsen D, Rothganger J, Singer C, Albert J, Frosch M. Intuitive hypertext-based molecular identification of microorganisms. Lancet. 1999;353:291. DOIPubMedGoogle Scholar
- Siddiqi SH, Heifets LB, Cynamon MH, Hooper NM, Laszlo A, Libonati JP, Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol. 1993;31:2332–8.PubMedGoogle Scholar
- National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Approved standard M24-A. Wayne (PA): the Committee; 2003.
- Heifets L. Dilemmas and realities in drug susceptibility testing of Mycobacterium avium-Mycobacterium intracellulare and other slowly growing nontuberculous mycobacteria. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton (FL): CRC Press; 1991. p. 123–46.
- Suomalainen S, Koukila-Kähkölä P, Brander E, Katila ML, Pilonen A, Paulin L, Pulmonary infection by an unusual slowly growing nontuberculous mycobacterium. J Clin Microbiol. 2001;39:2668–71. DOIPubMedGoogle Scholar
- McMullan R, Xu J, Kelly M, Stanley T, Moore JE, Millar BC, Mycobacterium triplex pulmonary infection in an immunocompetent patient. J Infect. 2002;44:263–4. DOIPubMedGoogle Scholar